With imeglimin , the A1C level decreased by 0.5 % in 54.3 % of subjects vs. 21.6 % with placebo ( P < 0.001 ) , and 19.8 % of subjects receiving imeglimin achieved a decrease in A1C level of 7 % compared with subjects receiving placebo ( 1.1 % ) ( P = 0.004 ) .